Facilitators and barriers to the delivery of palliative care to patients with Parkinson’s disease: a qualitative study of the perceptions and experiences of stakeholders using the socio-ecological model
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Facilitators and barriers to the delivery of palliative care to patients with Parkinson’s disease: a qualitative study of the perceptions and experiences of stakeholders using the socio-ecological model ; volume:23 ; number:1 ; day:6 ; month:3 ; year:2023 ; pages:1-12 ; date:12.2023
BMC health services research ; 23, Heft 1 (6.3.2023), 1-12, 12.2023
- Urheber
-
Chen, Yiping
Zhang, Ru
Lou, Yan
Li, Wei
Yang, Hui
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12913-023-09203-2
- URN
-
urn:nbn:de:101:1-2408290838409.238521726350
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Yiping
- Zhang, Ru
- Lou, Yan
- Li, Wei
- Yang, Hui
- SpringerLink (Online service)
Ähnliche Objekte (12)
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Reply to the Letter to the Editor “The Microbiota in Parkinson’s Disease: Ranking the Risk of Heart Disease”
How to optimize the treatment of early stage Parkinson’s disease
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease
The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease
Definition and diagnosis of Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
The psychometric properties of the Chinese version of the Parkinson Anxiety Scale (C-PAS) among Parkinson’s disease
The neurophysiological brain-fingerprint of Parkinson’s disease
Cannabinoids in the Treatment of Parkinson’s Disease
Tau in the Pathophysiology of Parkinson’s Disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Reply to the Letter to the Editor “The Microbiota in Parkinson’s Disease: Ranking the Risk of Heart Disease”
How to optimize the treatment of early stage Parkinson’s disease
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease
The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease
Definition and diagnosis of Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
The psychometric properties of the Chinese version of the Parkinson Anxiety Scale (C-PAS) among Parkinson’s disease
The neurophysiological brain-fingerprint of Parkinson’s disease
Cannabinoids in the Treatment of Parkinson’s Disease
Tau in the Pathophysiology of Parkinson’s Disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Reply to the Letter to the Editor “The Microbiota in Parkinson’s Disease: Ranking the Risk of Heart Disease”
How to optimize the treatment of early stage Parkinson’s disease
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease
The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease
Definition and diagnosis of Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
The psychometric properties of the Chinese version of the Parkinson Anxiety Scale (C-PAS) among Parkinson’s disease
The neurophysiological brain-fingerprint of Parkinson’s disease
Cannabinoids in the Treatment of Parkinson’s Disease